Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05678673 · ClinicalTrials.gov registry record · Phase 3
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
A Phase 3 study of Non-Clear Cell Renal Cell Carcinoma, sponsored by Exelixis.
- Active
- Registry status
- Phase 3
- Development phase
- 317
- Enrollment target
- 20
- Study locations
NCT05678673 is a Phase 3 study of Non-Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 317 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT05678673, a Phase 3 study of Non-Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Exelixis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 317 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG XL092
- DRUG Sunitinib Malate
Study Locations (20)
Other
- Exelixis Clinical Site #44 - Buenos Aires
- Exelixis Clinical Site #35 - CABA
- Exelixis Clinical Site #90 - Córdoba
- Exelixis Clinical Site #51 - Santa Fe
New South Wales
- Exelixis Clinical Site #94 - Albury
- Exelixis Clinical Site #97 - Camperdown
- Exelixis Clinical Site #98 - Liverpool
- Exelixis Clinical Site #95 - Macquarie
California
- Exelixis Clinical Site #1 - Duarte
- Exelixis Clinical Site #164 - Newport Beach
- Exelixis Clinical Site #162 - San Francisco
New York
- Exelixis Clinical Site #161 - Buffalo
- Exelixis Clinical Site #58 - New York
- Exelixis Clinical Site #15 - New York
Colorado
- Exelixis Clinical Site #163 - Aurora
Florida
- Exelixis Clinical Site #55 - Jacksonville
Ohio
- Exelixis Clinical Site #42 - Cleveland
Texas
- Exelixis Clinical Site #31 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05678673
The ClinicalTrials.gov registry entry for NCT05678673 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT05678673 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, New South Wales, California.
Frequently Asked Questions
What is clinical trial NCT05678673 about?
NCT05678673 is a clinical study titled "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma". This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.
What is the current status of trial NCT05678673?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 317 participants. The study started on 2023-01-01. Estimated completion is 2028-06.
What conditions does trial NCT05678673 study?
This clinical trial studies the following conditions: Non-Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT05678673?
The interventions under investigation include: Nivolumab (DRUG), XL092 (DRUG), Sunitinib Malate (DRUG).
Who is sponsoring clinical trial NCT05678673?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05678673 being conducted?
This trial has 20 study locations across California, Colorado, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.